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Abstract: In Duchenne muscular dystrophy (DMD), the absence of dystrophin from the dystrophin-
associated protein complex (DAPC) causes muscle membrane instability, which leads to myofiber
necrosis, hampered regeneration, and chronic inflammation. The resulting disabled DAPC-associated
cellular pathways have been described both at the molecular and the therapeutical level, with the
Toll-like receptor nuclear factor kappa-light-chain-enhancer of activated B cells pathway (NF-
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and absorb shocks during muscle contraction [4,5]. This shock-absorbing effect of the 
DAPC is compromised in DMD patients and causes cell membrane instability, which start 
as soon as the fetus can move in utero. The DAPC is composed of dystrobrevins, dystro-
glycans, sarcoglycans, sarcospan, and syntrophin. The most widely used murine model 
for DMD are mdx mice that carry a nonsense mutation in exon 23 of the dystrophin gene. 
However, the disease phenotype of this murine model is milder than the human condi-
tion. While humans display progressive muscle weakness, mice develop active muscle 
tissue degeneration and regeneration at a young age, which later on continues at a slower 
pace. The DAPC is affected in DMD and mdx displaying both common and differential 
deficiencies (Table 1). In mdx mice, α- and β-dystroglycans are unstable, whereas expres-
sion of α-, β-, γ- and δ-sarcoglycans, sarcospan and α1-syntrophin is weak [6–11] and ex-
pression of β1-syntrophin and α-dystrobrevin is absent [12–14]. In DMD patients, the fol-
lowing DAPC proteins are less expressed to sometimes absent: α- dystroglycan, α-sarco-
glycan, sarcospan, α1-syntrophin, α-dystrobrevin, and neuronal nitric oxide synthase 
(nNOS) [10,15–22]. The role of nNOS instability in mdx pathology is controversial. Indeed, 
normal nNOS activity reduced dystrophic symptoms in one mdx study, whereas mdx 
mice crossed with NOS-null mice showed no difference in muscle pathology when com-
pared to mdx mice [23–25]. β-dystroglycan is still present in DMD skeletal muscle tissue 
[6] and expression studies of β1-syntrophin in DMD patients are not yet available. Both
β-dystroglycan and syntrophin function as signaling proteins. More specifically, β-dys-
troglycan signals to Ras-related C3 botulinum toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such as voltage-gated sodium channels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
α-dystrobrevin weak absent
Hampered signal transduction and cellular pathways have been described in DMD 
with Toll-like receptor/tumor necrosis factor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)-nuclear factor kappa-light-chain-enhancer of the activated B cell pathway (NF-Ƙ  ), Janus kinase/signal transducer and activator of transcription proteins, and the 
trans-forming growth factor-β (TGF-β) pathways having been extensively studied and 
consid-ered for therapeutic targeting [28,29]. Due to the important inflammatory aspect 
of the disease, glucocorticoids (GCs) are the drugs of choice in DMD with their major 
mode of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B),
Janus kinase/signal transducer and activator of transcription proteins, and the transforming growth
factor-β pathways receiving the most attention. In this review, we specifically focus on the protei
kinase A/ mitogen-activated protein kinase/nuclear factor of activated T-cells 5/organic osmolytes
(PKA-p38MAPK-NFAT5-organic osmolytes) pathway. This pathway plays an important role in
osmotic homeostasis essential to normal cell physiology via its regulation of the influx/efflux of
organic osmolytes. Besides, NFAT5 plays an essential role in cell survival under hyperosmolar
conditions, in skeletal muscle regeneration, and in tissue inflammation, closely interacting with
the master regulator of inflammation NF-
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B. We describe the involvement of the PKA-p38MAPK-
NFAT5-organic osmolytes pathway in DMD pathophysiolo y and provide a clear overview of which
therapeutic molecules could be of potential benefit to DMD pati nts. We onclude that modulation of
the PKA-p38MAPK-NFAT5-organic osmolytes pathway could be developed as supportive treatment
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1. Introduction
Duchenne muscular dystrophy (DMD) is a severe X-linked disorder usually recog-
nized in early childhood, characterized by progressive skeletal muscle weakness causing
loss of ambulation by early adolescence. In addition to the skeletal muscle, the disorder
also involves cardiac and respiratory muscles. DMD is caused by disruptive mutations in
the DMD gene, resulting in the absence of its protein product dystrophin from muscle fiber
membranes. Contraction damages the dystrophin-deficient muscle fibers, generating cycles
of muscle fiber necrosis and regeneration that fail to restore the tissue, leading to fibrosis
and fatty replacement. Absence of dystrophin distorts anchoring of the extracellular matrix
to the myofiber cytoskeleton [1–3]. Dystrophin is part of a larger group of transmembrane
proteins, called the dystrophin associated protein complex (DAPC), which has the ability to
receive and transduce signals from in- and outside the myofiber and absorb shocks during
muscle contraction [4,5]. This shock-absorbing effect of the DAPC is compromised in DMD
patients and causes cell membrane instability, which start as soon as the fetus can move in
utero. The DAPC is composed of dystrobrevins, dystroglycans, sarcoglycans, sarcospan,
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and syntrophin. The most widely used murine model for DMD are mdx mice that carry a
nonsense mutation in exon 23 of the dystrophin gene. However, the disease phenotype of
this murine model is milder than the human condition. While humans display progressive
muscle weakness, mice develop active muscle tissue degeneration and regeneration at a
young age, which later on continues at a slower pace. The DAPC is affected in DMD and
mdx displaying both common and differential deficiencies (Table 1). In mdx mice, α- and β-
dystroglycans are unstable, whereas expression of α-, β-, γ- and δ-sarcoglycans, sarcospan
and α1-syntrophin is weak [6–11] and expression of β1-syntrophin and α-dystrobrevin is
absent [12–14]. In DMD patients, the following DAPC proteins are less expressed to some-
times absent: α- dystroglycan, α-sarcoglycan, sarcospan, α1-syntrophin, α-dystrobrevin,
and neuronal nitric oxide synthase (nNOS) [10,15–22]. The role of nNOS instability in mdx
pathology is controversial. Indeed, normal nNOS activity reduced dystrophic symptoms
in one mdx study, whereas mdx mice crossed with NOS-null mice showed no difference in
muscle pathology when compared to mdx mice [23–25]. β-dystroglycan is still present in
DMD skeletal muscle tissue [6] and expression studies of β1-syntrophin in DMD patients
are not yet available. Both β-dystroglycan and syntrophin function as signaling proteins.
More specifically, β-dystroglycan signals to Ras-related C3 botulinum toxin substrate 1
(Rac1) small guanosinetrifosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK)
through growth factor receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex
linked to dystrophin and regulates signaling proteins such as voltage-gated sodium chan-
nels along with plasma membrane calcium pumps and nNOS. DAPC also interacts with
calmodulin which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) compo-
nents in Duchenne muscular dystrophy (DMD) and in the mdx mouse.
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B),
Janus kinase/signal transducer and activator of transcription proteins, and the transfo m-
ing growth factor-β (TGF-β) pathways having been extensively studied and considered
for therapeutic targeting [28,29]. Due to the important inflammatory aspect of the disease,
glucocorticoids (GCs) are the drugs of choice in DMD with their major mode of action
residing in the binding to NF-
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factor of activated T-cells (NFAT) [30,31]. The NFAT group consists of five transcripti
factors belonging to the larger ReI family which also en ompasses NF-
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con id-ered for therap utic targeting [28,29]. Du  to  important inflammatory aspect 
of the disease, glucocorticoids (GCs) are the drugs of choice in DMD with their major 
mode of action residing in the b nding to NF-ƘB and MAPKs along with nucl ar 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B [32]. NFAT5 i a multifaceted protein,
which tightly controls cell volume in order to remain ins de the homeostati range. It
controls cell growth in embryogenic tissue, mediates nflammation and protects c lls fr m
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oxidative stress and metabolic aberrations due for instance to excessive caloric intake. It
therefore deserves the name of immunometabolic stress protein [33].
In DMD, NFAT5 could play a role in permanent extracellular matrix protein pro-
duction by fibroblasts [34] and could serve as a binding site for glucocorticoid receptor
(GR), possibly explaining its anti-proliferative role in fibrosis formation [35]. In healthy
myoblasts, NFAT5 is an essential protein in cell migration during myogenesis, but in in-
flammatory disease pro-inflammatory cytokines hamper normal NFAT5 physiology [36,37].
In lymphocytes and renal medullary cells, hyperosmotic stimuli activate the guanine nu-
cleotide exchange factor Brx, also named A-kinase anchor protein 13 (AKAP13), which
belongs to the protein kinase A (PKA) family and is linked with Rac1. In turn, it activates
p38αMAPK, glycogen synthase kinase 3 (GSK-3), and NFAT5 [38,39]. The pathway also
involves osmolytes, which are protective solutes that safeguard cells from perturbations
in volume and osmotic imbalance. Osmolytes are involved in normal skeletal muscle
physiology and become dysregulated in DMD (Table 2). Dystrophin deficiency perturbs
the muscle cell’s osmotic balance, probably due mostly to the passive efflux of osmolytes
through the leaky plasma membranes. Activation of the osmolyte pathway in DMD may
act to stabilize proteins and counteract tissue injury.
Table 2. The role of organic osmolytes in skeletal muscle physiology and in Duchenne muscular
dystrophy (DMD) and its mouse model mdx.












































In this review, we explore the PKA-p38MAPK-NFAT5-organic osmolytes pathway in
DMD by providing an overview of the current knowledge and research gaps that need
to be filled. Indeed, DAPC instability activates PKA. In turn, PKA activates both GSK3
and p38MAPK. The latter has an influence on NFAT5. Upon translocation to the nucleus,
NFAT5 has the ability to activate genes coding for organic osmolytes carriers. A graphical
representation of this overview is shown in Figure 1.
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the schematic representation of the protein kinase A/mitogen-activated protein kinase/nuclear factor of activated T-cells 5
(PKA-p38MAPK-NFAT5)-organic osmolytes pathway members representing potential therapeutic targets either to stimulate
(green) or to inhibit (red) for treating DMD.
2. The PKA-p38MAPK-NFAT5- Pathway as a Therapeutic Target in Duchenne
Muscular Dystrophy
2.1. Protein Kinase A
PKA regulates sug r, glycogen and lipid metabolism in the cell. In sk letal muscle
tissue, PKA is in close contact with the DAPC, more specifically w th α- and β dys-
trobrevin [40]. I mdx mice and DMD patients, PKA is downregulated along with the
muscle-specific A-kinase anchor protein (AKAP) named myospryn. PKA activity is re-
duced by 50% in mdx mice [41].
PKA upregulating molecules, urocortins (Ucns), have been succ ssfully u ed in mdx
mice. Ucns are neuropeptides involved in inflammatory responses, anxiety d ren l
physiology [42]. In mdx, Ucns were administered daily s.c. for two- to three-week-old
mdx mice, resulting in improved muscle resistance to mechanical stress, increased skeletal
muscle ass, reduced necrosis in the diaphragm and slow- and fast-twitch muscles, along
with normalized calcium influx [43]. When combined with anti-interleukin-6 receptor anti-
body (xIL-6R), Ucns improved the impaired force in mdx diaphragms, along with muscle
shortening and mechanical work production [44]. This combination also resulted in the
recovery of respiratory function and pharyngeal dilator muscle force in mdx mice [45,46].
Both molecules have not been tested yet in DMD patients.
2.2. P38 Mitogen-Activated Protein Kinase
P38 MAPK is responsive to cytokines, UV-light, osmotic perturbations and heat shock
and plays an important role in apoptosis. In skeletal muscle, constitutive p38 MAPK
activation in satellite cells, as seen during ageing, impairs muscle regeneration [47,48]. Very
recently, p38 MAPK has been shown to induce cell fusion in myotube formation. Besides,
in aging and chronic inflammation, excessive p38 MAPK activation could disrupt skeletal
muscle homeostasis, leading to muscle pathology and atrophy [49]. The exact role of p38
MAPK in mdx and DMD is not clear, but a protective role for p38 MAPK signaling is
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suggested [50]. In mdx mice, p38 MAPK is phosphorylated (p-p38) [51–54]. Two studies
describe a decrease in p-p38 compared to wild type mice at rest [51,54], whereas one study
mentions increased phosphorylation in mdx mice compared to wild type mice at rest [53].
The levels of p-p38 increase after treadmill exercise in mdx mice compared to wild type [52].
In one DMD patient, p-p38 was increased compared to normal individuals [55].
p38 MAPK-targeted therapeutic agents have been used in mdx mice with good results:
free radical scavenger α-lipoic acid (ALA)/L-carnitine (L-CAR), p38 inhibitor SB203580
and the cyclooxygenase (COX)-2 inhibitor celecoxib [51,53,56]. Carnitine is a fundamental
source of acetyl groups. As it acts by transporting long-chain fatty acids into the mito-
chondrial matrix, its bioavailability is directly related to the rate of ß-oxidation, which was
found to be slow in DMD muscle [57], as were reduced carnitine levels [58]. With 95% of
carnitine residing in skeletal muscle and since this tissue largely depends on fatty acids
as an energy source, its use has been tried in DMD (50mg/kg/day) in an unsuccessful
trial [59]. In Becker muscular dystrophy (BMD), a low level of carnitine was found and
supplementation has been observed to be beneficial in some cases [60]. Carnitine might be
helpful for cardiomyopathy but trials need more strict correlations and biomarkers. The
use of steroid, carnitine and branched chain amino acids in DMD has been reviewed in
2015 [61]. ALA/L-CAR induced a reduction in the level of p-p38 in mdx diaphragms [51]
and SB203580 increased the survival of mdx myofibers exposed to oxidative stress [53,56].
A four weeks, treatment of six-week-old mdx mice with celecoxib resulted in a fiber type
switch from fast to slow phenotype and enhanced muscle fiber integrity and muscle
strength. Increased utrophin A expression was noticed in the diaphragm, heart and tibialis
anterior [56]. In mdx mice, utrophin reduces the dystrophic phenotype [62]. These three
molecules have not yet been investigated in clinical trials involving DMD patients.
2.3. Glycogen Synthase Kinase 3 Beta
The serine/threonine protein kinase glycogen synthase kinase 3 (GSK-3) is ubiqui-
tously expressed and exists in two isoforms, α and β. GSK-3β is a key regulator of a
wide range of cellular functions, with a role in neuronal cell development and energy
metabolism [63]. In skeletal muscle, it is involved in muscle regeneration [64,65], and its
ablation results in accelerated regeneration after atrophy is induced by disuse [66]. Both in
mdx mice and in a canine DMD model, the GSK-3 levels are elevated [67–69]. The exact
role played by GSK-3 in DMD has not been fully investigated [69], but GCs are believed to
interact with GSK-3β [70].
The selective GSK-3 peptide inhibitor, L803-mts, increased glucose transporter type 4
(GLUT4) expression in murine muscle tissue; the transporter is altered in DMD and seems
to be involved in DMD insulin resistance [71,72]. No further data on GSK-3-targetted
treatment is currently available for DMD.
2.4. Nuclear Factor of Activated T-Cells 5
NFAT5 or tonicity-responsive enhancer binding protein (TonEBP) is strongly present in
DMD skeletal muscle tissue in nuclei of small myofibers and fibers with central nuclei [55],
which could be linked to its role in muscle regeneration [36]. Staining with a Ser 1197-
phosphorylated NFAT5 antibody shows this phosphorylation occurs around myonuclei,
on the cell membrane and throughout the sarcoplasm in DMD tissue, especially in small
fibers. In vascular smooth muscle cells, this phosphorylation appears to prevent NFAT5
from translocating to the nucleus and accumulates in the cytoplasm [73]. NFAT5 nuclear
translocation is important during myogenesis [36]. This absence of NFAT5 translocation
was observed in normal myoblasts exposed to pro-inflammatory cytokines, where NFAT5
formed aggregates in the sarcoplasm, without showing increased expression [37], and may
also be present in DMD fibers, which are chronically exposed to inflammatory cytokines.
This could lead to the decreased total NFAT5 protein expression in DMD patients we
observe using immunoblotting. In the 15 muscle samples tested, we found constitutive
expression in all 11 healthy controls but only in one of the four DMD samples a prominent
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band was present (Figure 2). NFAT5 has not been investigated in mdx mice so far. When
proteins form pathogenic aggregates in the cytoplasm, one therapeutic option that could
be considered are protein specific nanobodies [74], which will be discussed further on.
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Western blots are shown for skeletal biopsies from four patients affected with Duchenne muscular
dystrophy (DMD) and from one representative healthy control (C). Total protein extracts were trans-
ferred to nitrocellulose membranes following electroblotting. Overnight incubation with 2 µg/mL
mouse monoclonal IgG2a anti-NFAT5 (F-9, Santa Cruz) and 0.4 µg/mL anti-GAPDH (Sigma-Aldrich,
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was followed by immunoreaction detecti n with chemilumi escence (WesternBright™ Sirius, Ad-
vansta, Menlo Park, CA, USA) and Proxima 2650 (Isogen Life Science, De Meern, The Netherlands).
2.5. Factors Downstream of Nuclear Factor of Activated T-Cells 5
NFAT5 is known for activating genes that code for TNF-α, heat shock protein 70
(hsp70), and members of osmolyte pathways, in response to hypertonic stimuli [32,75,76].
Under hypertonic conditions, binding of NFAT5 to tonicity-responsive enhancer sequences
located at the promotor region results in the increased gene transcription of osmolyte
pathway members. In the next sections, individual osmolyte pathway members and their
corresponding osmolytes are discussed in detail [77–91].
2.5.1. Taurine Transporter
The taurine transport r (TauT or SLC6A6) is principally located on the cell membrane
and transports taurine or 2-aminoethyl sulfonic acid from the extracellular environment
into the cell. Taurine is an organic osmolyte and functions as an osmoregulator, but
lso plays a r le in calcium homeostasis and exerts anti-inflammatory and antioxidant
actions [92–97]. In DMD patients, protein levels of TauT are increased, particularly in
the CD56+ small regenerating muscle fibers [55], whereas changes in taurine plasma and
urinary levels, indicative of increased taurine excretion, have been reported [96,97]. In mdx
mice, hampered regulation of the taurine pathway is manifested by a significant decrease
of both taurine and its transporter in muscle tissue.
As a possible correlation exists between low taurine levels and muscle
impairment [95,98–102], increasing intramuscular taurine levels could improve the mdx dis-
ease phenotype. Indeed, studies have found that taurine treatment in mdx mice improved
histopathological features such as necrosis [102–104] and reduced markers of inflamma-
tion and oxidative damage [104–106]. Interestingly, Barker et al. reported the favorable
effects of prenatal taurine administration (2.5% w/v) in young mdx mice (aged four weeks),
whereas the beneficial effect of taurine on histopathological level was almost completely
abolished in mice sacrificed at 10 weeks. While intramuscular taurine levels were increased
(+25%) upon treatment in four-week-old mice in comparison to untreated mdx mice, the
taurine levels were decreased (−22%) in adult treated mdx mice [107]. High taurine
supplementation could induce a reduction in both the expression and activity of its trans-
porter [94,108–110], which might explain lower intramuscular taurine levels. In the study
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by Barker et al., however, the protein expression of TauT was reported unchanged [107].
Taurine supplements might also exert beneficial effects on muscle strength. An increase in
normalized fore limb muscle force measured by grip strength has been reported [103,111],
but the in vitro measurement of specific muscle force was only able to show ameliorated
muscle strength in young mdx mice [107], and not in adult mice [103,107]. Furthermore, a
synergistic effect of taurine (1 g/kg) and α-methylprednisolone (1 mg/kg) on fore limb
strength has been observed in mdx mice [112].
Taurine was able to improve histopathological features and muscle strength in the
mdx mouse model and thus makes an interesting compound for the treatment of DMD.
To our knowledge, no clinical trials have been conducted to evaluate the effect of taurine
in DMD patients; however, the use of taurine in other conditions such as peripartum
cardiomyopathy, obesity, etc. has been investigated (https://www.clinicaltrials.gov/,
accessed on 10 February 2021).
2.5.2. Betaine Gamma Aminobutyric Acid Transporter
The betaine gamma aminobutyric acid transporter (BGT or SLC6A12) transports
betaine and to a lesser extent gamma aminobutyric acid (GABA) into cells. Betaine is an
osmolyte that counters osmotic stress, and in addition acts as a methyl group donor in the
conversion of homocysteine to dimethylglycine and methionine in the mitochondria of
liver and kidney cells [80–83,93]. To our knowledge, betaine levels in the muscles of DMD
patients have not been investigated; however, the increased expression of BGT in the small
regenerating and atrophic muscle fibers of DMD patients has been reported, while staining
was absent in control muscle tissues [93].
Betaine influences proliferation and differentiation in C2C12 cells [113,114]. The effect
of betaine on proliferation and the differentiation in C2C12 myoblasts is abolished in the
presence of 5-aza-2 deoxycytidine, a methylation inhibitor, which corroborates the hypoth-
esis that betaine could regulate genes involved in skeletal muscle formation via epigenetic
DNA methylation [113]. Furthermore, betaine might alter the distribution between fast-
and slow-twitch muscle fibers in favor of slow-twitch myofibers. Slow-twitch fibers are
more fatigue-resistant and contain more mitochondria, required for aerobic respiration.
Betaine was reported to induce an upregulation of slow-twitch genes [113], presumably
by the induction of NFATc1 and the subsequent attenuation of MyoD transcription. On
the contrary, transcription of MyoD1 is stimulated in the breast muscle of partridge shank
broiler chickens when supplemented with betaine [115]. Dose-dependent effects of betaine
and/or differences in the metabolism between species might explain these conflicting
results of betaine supplementation on MyoD transcription. In addition, betaine might exert
beneficial effects on fatty tissue deposition. Betaine supplementation in mice significantly
decreased the percentage of fat mass, whereas lean body mass of mice was increased [113].
Similar results were obtained in a mouse model for obesity. Betaine was able to reduce
whole body fat, specifically perirenal, inguinal and gonadal fat, together with inflammatory
stress-related genes such as IL-1, IL-6, CXCL13, etc. [116]. Betaine might affect the fatty
acid synthesis pathway in muscle and was able to prevent a build-up of intramyocellular
lipids. However, Wu et al. described increased lipid accumulation in vitro upon betaine
supplementation [117]. These conflicting results might be attributed to differences between
in vitro and in vivo models. To note, higher betaine intake in humans is associated with
lower body fat [118,119].
Besides a reduction in fat mass, some researchers have reported increased skeletal
muscle mass and endurance, both in mice and in humans, upon betaine supplementa-
tion [113,118–120]. Other beneficial effects of betaine supplementation on skeletal muscle
have also been reported. For example, betaine exerted protective effects against skeletal
muscle apoptosis caused by chronic alcohol overconsumption. Betaine treatment was able
to significantly reduce cytochrome C-release, calpain activity, TNF-α, NF-
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DAPC is compromised in DMD patients and causes cell membrane instability, which start 
as soon as the fetus can move in utero. The DAPC is composed of dystrobrevins, dystro-
glyca s, sarcoglycans, sarcospan, and syntrophin. The most widely used murine model 
for DMD are mdx mice that carry a nonsense mutation in exon 23 of the dystrophin gene. 
However, the disease phenotype of this murine model is milder than the human condi-
tion. While humans display progressive muscle weakness, mice develop active muscle 
tissue degeneration and regeneration at a young age, which later on continues at a slower 
pace. The DAPC is affected in DMD and mdx displaying both common and differential 
deficiencies (Table 1). In mdx mice, α- and β-dystroglycans are unstable, whereas expres-
sion of α-, β-, γ- and δ-sarcoglycans, sarcospan and α1-syntrophin is weak [6–11] and ex-
pression of β1-syntrophin and α-dystrobrevin is absent [12–14]. In DMD patients, the fol-
lowing DAPC proteins are less expressed to sometimes absent: α- dystroglycan, α-sarco-
glycan, sarcospan, α1-syntrophin, α-dystrobrevin, and neuronal nitric oxide synthase 
(nNOS) [10,15–22]. The role of nNOS instability in mdx pathology is controversial. Indeed, 
normal nNOS activity reduced dystrophic symptoms in one mdx study, whereas mdx 
mice crossed with NOS-null mice showed no difference in muscle pathology when com-
pared to mdx mice [23–25]. β-dystroglycan is still present in DMD skeletal muscle tissue 
[6] and expression studies of β1-syntrophin in DMD patients are not yet available. Both
β-dystroglycan and syntrophin function as signaling proteins. More specifically, β-dys-
troglycan signals to Ras-related C3 botulinum toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such as voltage-gated sodium channels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
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consid-ered for therapeutic targeting [28,29]. Due to the important inflammatory aspect 
of the disease, glucocorticoids (GCs) are the drugs of choice in DMD with their major 
mode of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B, and creatine
kinase levels [121]. Betaine supplementation might affect inflammation, skeletal uscle
differentiation and lipid accumulation and it could therefore be worthwhile to expl re
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using it as a supportive treatment option in DMD. Betaine is already approved by the Food
and Drug Administration (FDA) as an orphan drug for the treatment of homocystinuria
but has not yet been tried in DMD.
2.5.3. Sodium/Myo-Inositol Co-transporter
The sodium/myo-inositol co-transporter (SLC5A3 or SMIT) transports myo-inositol
(MI) into the cell. MI is a cyclic polyol and exerts numerous physiological functions.
Besides its function as an osmolyte, protecting the cell against osmotic stress, MI can be
phosphorylated to phosphatidylinositol 4,5-biphosphate (PIP2). PIP2 is a component of
the plasma membrane and plays an important role in signal transduction. PIP2 can be
further metabolized into diacylglycerol (DAG) or in inositol-(1,4,5) trisphosphate (IP3) that
triggers the release of Ca2+ [122,123]. Protein levels of SMIT are readily detected in muscle
tissue of DMD patients, in contrast to healthy subjects. Furthermore, immunofluorescent
staining in muscle fibers of DMD patients revealed the presence of SMIT in a large part
of muscle fibers and inflammatory cells (e.g., CD68+ macrophages and, to a lesser extent,
CD206+ macrophages and T cells) [55,93].
The therapeutic effects of MI have been investigated primarily in the context of
diabetes mellitus, a disease characterized by high glucose blood levels. Supplementation
with MI in glucose-loaded mice caused a decrease in plasma glucose levels [124]. Similar
beneficial effects of MI supplementation in obese insulin-resistant Rhesus monkeys on
plasma glucose levels have been observed [125]. An MI-induced plasma glucose uptake in
myotubes could, however, not be shown in vitro [126], which led to the hypothesis that
the effect requires conversion of MI to D-chiro-inositol [124]. Rodriguez et al. reported
hyperinsulinemia and insulin resistance in, respectively, 48.5% and 36% of DMD/Becker
patients [72]. MI supplements have, however, not yet been tried in DMD patients.
2.5.4. Aldose Reductase
Aldose reductase is an enzyme that catalyzes the reduction of glucose to sorbitol, the
first reaction of the polyol pathway. Later, it was shown that its specificity was not limited
to glucose and that the enzyme has a wide range preference for hydrophobic substrates
such as steroids and lipid-derived/hydrophobic aldehydes [127–133]. Aldose reductase
expression is high in skeletal muscle [134] and is increased even further in the muscle of
DMD patients [55,93]. Similarly, an upregulation of aldose reductase is observed in the
cardiac tissue of ageing mdx mice [135].
The role of sorbitol and aldose reductase is most extensively studied in models for
diabetes. Elevation of sorbitol by 90% has been reported in the skeletal muscle of diabetic
rats [136]. Supposedly, a decrease in the availability of adenosine triphosphate (ATP)
molecules related to increased polyol pathway activity in diabetes might be associated
with muscle dysfunction. Treatment with an aldose reductase inhibitor restored sorbitol
levels to normal and had beneficial effects on relaxation and to a lesser extent on the
contraction of skeletal muscle [136]. Contrastingly, insulin treatment can prevent rising
sorbitol levels in diabetic rats but is incapable of ameliorating muscle strength in a signifi-
cant manner [137,138]. Thus, the precise role of sorbitol on skeletal muscle dysfunction in
diabetes is not entirely clear.
Furthermore, aldose reductase inhibition is also examined as a treatment for diabetes-
induced vascular inflammation. Under hyperglycaemic conditions, NF-
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β-dystroglycan and syntrophin function as signaling proteins. More specifically, β-dys-
troglycan signals to Ras-related C3 botulinum toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such as voltage-gated sodium channels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
α-dystrobrevin weak absent
Hampered signal transduction and cellular pathways have been described in DMD 
with Toll-like receptor/tumor necrosis factor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)-nuclear factor kappa-light-chain-enhancer of the activated B cell pathway (NF-Ƙ  ), Janus kinase/signal transducer and activator of transcription proteins, and the 
trans-forming growth factor-β (TGF-β) pathways having been extensively studied and 
consid-ered for therapeutic targeting [28,29]. Due to the important inflammatory aspect 
of the disease, glucocorticoids (GCs) are the drugs of choice in DMD with their major 
mode of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B activity is
enhanced in cultured vascular smooth muscle cells (VSMC) of rats. The re ea ch of
Ramana et al. demonstrated that sorbinil, an aldose reductase inhibitor, abrogates high
glucose mediated NF-
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and absorb shocks during muscle contraction [4,5]. This hock-absorbing effect of the 
DAPC is compromised in DMD patients and causes cell membrane instab lity, which start 
as soon as the fetus can move in utero. The DAPC is c mposed of ystrobrevi s, dystro-
glycans, sarcoglycans, sarcospan, and syntrophin. The most widely used murine mod l 
for DMD are mdx mice that carry a nonsense muta ion in ex n 23 of the dystrophin gene. 
However, the disease phenotype of this murine mode  is milder than the human condi-
tion. While humans display progressive muscle w akness, mice dev lop active uscle 
tissue dege eration and regener tion at a young age, which later on co tinues at a slower 
pace. The DAPC is affected in DMD nd mdx displaying both common and differential 
deficiencies (Table 1). In mdx mice, α- and β-dystroglyca s are unstable, whe as expres-
sion of α-, β-, γ- and δ-sarcoglycans, sarcospan and α1-sy trophin is weak [6–11] and ex-
pression of β1-syntrophin and α-dystrobrevin is abse t [12–14]. In DMD patients, the fol-
lowing DAPC proteins are less ex ressed t  sometimes abse t: α- dystroglycan, α-sarco-
glycan, sarcospan, α1-syntrophin, α-dystrobrevin, and neuronal nitric oxide synthase 
(nNOS) [10,15–22]. The role of nNOS instability in mdx path logy is controversial. Indeed, 
normal nNOS activity reduced dystrophic symptoms in one mdx study, whereas mdx 
mice crossed with NOS-null mice showed no difference in muscle p thology when com-
pared to mdx mice [23–25]. β-dystroglycan is still present in DMD skeletal muscle tissue 
[6] and expression studies of β1-syntrophin in DMD patients are not yet availabl . Both
β-dystroglycan and syntrophin function as signaling pro eins. More specifically, β-dys-
troglycan signals to Ras-related C3 botulinum toxin substrate 1 (Rac1) small uanosi etri-
fosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such as voltage-gated sodium channels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
α-dystrobrevin eak absent
Hampered signal transduction and cellular pathways have been described in DMD 
with Toll-like receptor/tumor necrosis factor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)-nuclear factor kappa-light- hain-enhancer of the activated B cell pa hw y (NF-Ƙ  ), Janus kinase/signal transducer and activator of tran cription proteins, and the
trans-forming growth factor-β (TGF-β) pathways having been extensively studied and 
consid-ered for therapeutic targeting [28,29]. Due to the important inflammatory aspect 
of the disease, glucocorticoids (GCs) are the drugs of choice in DMD with their m jor 
mode of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B activity presumably by interfering with the phosp orylation
of I
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and absorb shocks during muscle contraction [4,5]. This shock-absorbing ffect of the 
DAPC is compromised in DMD patients d causes cell membrane instability, whic  start 
as soon as the fetus can move in utero. The DAPC is composed of dystrobrevins, dystro-
glycans, sarcoglycans, arcospan, and syntrophin. The most widely used murine model 
for DMD ar  mdx mice that carry a nonsens  mutation in exon 23 f the dystroph n gene. 
However, the disease phenotype of his murine m del is milder han th  human ondi-
tion. Whil  humans display pr gressive muscle weak ess, mice dev lop a tive muscle 
tissue degeneration  reg nerat on at a young age, which l ter on c tinues at a sl wer 
pace. The DAPC is af e ted n DMD and mdx displaying both common and differenti l 
d ficienci s (Table 1). In mdx mice, α- a d β-dystroglycans are u stabl , wherea  expres-
sion of α-, β-, γ- and δ- arcoglycans, sarcospan and α1- yntrophin is weak 6–1 ] and ex-
pression of β1-syntr phin and α-dystrobrevin is absent [12–14]. In DMD p tients, the fol-
lowing DAPC proteins re less ex ressed to sometimes absent: α- dystroglycan, α-s rco-
glycan, sarcospan, α1-syntrophin, α-dystrobrevi , and neuronal itric oxide synthase 
(nNOS) [10,15–22]. The role of nNOS instability in m x pathology is controversial. Indeed, 
normal nNOS activity reduced dystrophic symptom  in one mdx study, whereas mdx 
mice crossed with NOS-null ice showed no difference in muscle pathol y when com-
pared to mdx mice [23–25]. β-dy tr glycan is still present in DMD skeletal muscle tissue
[6] and expression studies of β1-syntrophin in DMD pa e ts are ot yet available. B th
β-dystroglycan and syntrophin func ion as signaling prote s. M re specific lly, β-dy -
troglycan signals to Ras-related C3 botulinu  xin substrate 1 (Rac1) small guanosine ri-
fosfaat (GTP)ase and to mitogen-activa d protein kinase (MAPK) throug  growth factor
receptor-bound protein 2 (Grb2). Syntrophin o ganize  a signalplex linked to dystrophin
and regulates signa ing prot ins such s voltage-gated sodium channels al ng wi h
plasma membrane calcium pumps and nNOS. DAPC also inter cts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expr ssion of the main dy trophin-ass ciated protei  compl x (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
α- ystrobrevin weak absent
Hampered signal transducti n and cellular pathways have been describ d in DMD
with Toll-lik  receptor/tumor necrosis f ctor α (TNF-α)/int rl uki  1β (IL-1β)/in rleukin
6 (IL-6)-nucl ar factor kappa-light-chain-enhancer of the ctiv ed B cell pathway (NF-Ƙ  ), Janus kinase/signal transducer and activator of transcription proteins, a d the 
trans-forming growth facto -β (TGF-β) athways having been extensively studied and 
consid-ered for therapeutic targ ting [28,29]. Due to the important inflamma ory asp ct 
of the disease, glucoc rticoids (GCs) are the drugs of choice in DMD with their major 
mode of action residing in the bi ding to NF-ƘB nd MAPKs a ong with uclear
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI f mily which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B-α and subsequent i hibitio of NF-
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and absorb shocks during muscle contraction [4,5]. This shock- bsorbing ffec  of the 
DAPC is compromised i  DMD patients and causes c ll m mbrane instability, which start 
as oon as the fetu  can move in utero. Th  DAPC i  composed f dy trobrevins, dystro-
glycans, sarc glycans, rcospan, and syntr phin. The m st widely used m rine model 
for DMD ar dx mice that carry a no s se mutation in exon 23 of the dystrophin gene. 
Howev r, the di ease phenotype of this urin  model is milder than the human condi-
tion. While humans display progressiv  uscle weakness, mi e develop active muscle 
tissue egeneratio  and regener tion at  young age, w ich later on continues at  slower 
pace. The DAPC is affected in DMD and mdx displaying both common and differential 
deficiencies (Table 1). In mdx mic , α- and β-dy troglycans are unstable, whereas expres-
si n of α-, β , γ- a d δ-sarcoglyc ns, sa cospan and α1-sy rophin is weak [6–11] an  ex-
p ssion of β1-syntrophin and α-dystrobrevin is absent [12–14]. In DMD patients, he fol-
lowing DAPC protei s are less expr ssed to somet mes absent: α- dystroglycan, α-sar o-
glycan, sarcospa , α1-syntrophin, α-dy trobrevi , and neuronal nitri  oxide synthase 
(nNOS) [10,15–22]. The role of NOS instability in mdx path logy is controversial. Indeed, 
norma  nNOS activity re uc d dystrophic symptoms in on  mdx study, whereas mdx 
mice crossed with NOS-null mic  sho ed o diff rence in muscle pa hology whe  com-
p red t  mdx mice [23–25]. β-dystroglycan is till present in DMD skeletal muscle tissu  
[6] and expression studies of β1-syntr phin i  DMD patients are not yet available. Both
β-dy troglycan and syntrophin function as signaling protein . More specifically, β-dys-
tr glycan signal  to Ras-related C3 botulinu  toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and to mitogen-activated protein inase (MAPK) through growth factor
recept r-bound protein 2 (Grb2). Syntrophin organizes a sig alplex linked to dystrophin
and regulates sig ali g protei s such as vol age-gated sodium channels alo g with
plasma embra e calcium pumps a d nNOS. DAPC also interacts with calmodulin
which is stimul ted by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Diffe ential ex ess on of t e ain dystr phin-associated protein complex (DAPC) com-
ponents in Duchenne uscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
α-dystrobrevin weak absent
H m red signal t nsduction an  ellular pathways hav  been described in DMD 
with T ll ke receptor/tum r ne is factor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)- uclea  factor kapp -light-chai - nhancer of he activated B c ll pathway (NF-Ƙ  ), Janus kinase/signal transduc r and activator of transcriptio  proteins, and the 
trans-forming growth factor-β (TGF-β) pathways having been extensi ely studied and 
nsid-er d for therap utic targeti g [28,29]. Due to e importan  inflammatory aspect 
of the diseas , glucocor icoids (GCs) ar  th  drugs of choice in DMD with their major 
mode of action residing in the bi ding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activat d T-cells (NFAT) [30,31]. The NFAT group 
consists of fiv tran-sc iption factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B translocati n o the nucleus. As exp cte ,
sorbinil prevents the expressi n of vascula cell adhesion molecule 1 (VCAM-1) and i -
tracellular adhesion m lec le 1 (ICAM-1), both ta ge genes of NF-
Biomedicines 2021, 9, x FOR PEER REVIEW 2 of 18 
and absorb ocks duri g uscle contraction [4,5]. This shock-absorbing effect of the 
DAPC is c mpro ised i  DMD pati nts a d c uses cell membrane instability, which start 
s s n s he fetu can mov  in uter . The DAPC is compos d of dystrobrevins, ystro-
glycan , sarcogly a s, sarcospan, and yntrophin. The m st widely sed murine model 
for DMD re mdx mic that c rry n ns ns  mut on in exon 23 f the dystrophin gene. 
However, the di ease ph notype of this murine model is milder than the human condi-
tion. While huma   progressiv  uscle weakness, mice develop active muscle 
tissu  d g ration and regenerati n at a young age, which later on continues at a slower 
pace. The DAPC is affected in DMD a d mdx displaying both c mmon and diff rential 
deficie cies (Table 1). In mdx mice, α- and β-dystroglycans are unstable, whereas expr s-
sion of α-, β-, γ- a d δ-sarcoglycans, sarcospan a d α1-syntrophin is weak [6–11] and ex-
p ess o  of β1- rophin α-dystrobrevin is abs nt [12–14]. I   patients, the fol-
lowing DAPC prot in are less expresse  to som times absent: α- dystroglycan, α-sarco-
glycan, sarcosp n, α1-syntrophin, α-dystrobrevin, a d euronal nitric oxide synthase 
(nNOS) [10,15–22]. The r le of nNOS instability in dx path logy is controversi l. Indeed, 
normal nNOS act vity re uced dystrophic symptoms in one mdx study, whereas mdx 
mice crossed with NOS-null m ce showed no difference in muscle pathology when com-
pared to mdx mic  [23–25]. β-dystroglycan is still present in DMD skeletal muscle tissue 
[6] and expression s udie  of β1-syntro hin in DMD pat en s are not yet available. Both
β-dystroglyca  and sy trophin function as si naling proteins. More specifically, β-dys-
tro lyc n signals to Ras-related C3 botul num toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and o mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound prote   (Grb2). Syntro in organizes a signalplex linked to dystrophin
and regulates signaling protei s such as voltage-gated sodium channels along with
plasma membran  calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by c lcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophin weak weak β1-syntrophin absent
α-dyst obrevin weak absent
Hampered signal t ansduction and c llular t s have bee  described in DMD 
with Toll-l ke r c pt r/tumor ecrosis f ctor α (TNF-α)/i terleukin 1β (IL-1β)/interleuki  
6 (IL-6)-nucle r fact r kappa-light-chain- hancer of the activated B cell pat way (NF-Ƙ  ), Ja us kinase/signal transduce  nd activator of transcription proteins, and the 
trans-forming growth factor-β ( GF-β) path ays having been extensively studied and 
co sid-ered for therapeutic t rgeting [28,29]. Due to the important inflammatory aspect 
of he disease, luc corticoids (GCs) are the drugs of choice in DMD with their major 
m de of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B, in h gh glucose
cultured VSMC’s. Interestingly, sorbinil is unabl to in ibit osmot c stres induce NF-
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and absorb h cks duri g m cle contraction [4,5]. This shock-abso bing effect of the 
DAPC is compromised in DMD patients and causes cell embrane instability, which start 
as soon as the fetus can move in tero. The DAPC is composed of dystrobrevins, dystro-
gly ans, s r oglyca s, arcospan, and syntr phin. The most widely used murine model 
for DMD re mdx mice that carry a nonse se mutatio  in exon 23 f the dystrophin gene. 
Howev r, t  disea e henotype of this urin model is mild r than the human condi-
ti n. Whi  humans isplay pro s ive muscle weakness, mice dev lop active muscle 
ti sue degenera i n an  reg neration at a y ung age, which later on continues at a slower 
pace. Th  DAPC is affected in DMD and mdx displaying both common an  differential 
defici ncies (Table 1). In mdx mice, α- and β-dystroglycans are unstable, whereas expres-
sion f α-, β-, γ  an  δ-sarcoglycans, arcospan and α1-syntrophin is weak [6–11] and ex-
pr ssion of β1-syntrophi  and α-dystrobr vin is absent [12–14]. In DMD patients, the fol-
l wing DAPC proteins are less expressed to sometimes absent: α- dystroglycan, α-sarco-
glycan, sarcospan, α1-syntr phin, α-dystrobrevin, and neuronal nitric oxide synthase 
(nNOS) [10,15–22]. The rol  of nNOS i stability in mdx pathology i  controversial. Indeed, 
ormal nNOS ac ivity reduced dystrophic symptoms in one mdx study, whereas mdx 
mice crossed with NOS-null m ce showed no difference in muscle pathology when com-
pared to mdx mice [23–25]. β-dystroglyca  is still pres nt in DMD skeletal muscle tissue 
[6] and ex ressio  studie of β1-sy trophin in DMD atients are not yet available. Both
β-dystroglyc n a d syntrophin function as signaling proteins. Mor  specifically, β-dys-
troglycan si nal  t  Ras-rel ted C3 b tulinum toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and  m togen-activate  protein k ase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such a  vol age-gated sodium channels along with
plasma membrane calciu  pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main ystr phin-associated protein complex (DAPC) com-
ponent  in Duchen e muscular dystrophy (DMD) and in the mdx mous . 













α1-syntrophin weak weak β1-syntrophin absent
α-dystrobrevin weak absent
Ha pered signal ra sduction and cel ular pathways have b en described in DMD 
wi h Toll-like rec ptor/tumor ec osis factor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)-nucl ar factor kapp -light-chain-e ancer of the activate B cell pathway (NF-Ƙ  ), J nus kinase/sign l transduc r and activa or of transcription proteins, and the 
trans-forming growth factor-β (TGF-β) pathw ys having been extensively studied and 
consid-ere  for ther peutic tar eting [28,29]. Due to the important inflammatory aspect 
f th  disease, glucocorticoids (GCs) are the drug of choice in DMD with their major 
mode o  action residing in the binding to NF-ƘB and M PKs along with nuclear 
slocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B
activity. Apparently, hypergly emic and hyperosmotic onditions med ate NF-
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a d absorb shocks during muscle contr cti n [4,5]. This shock-absorbing effect of the 
DAPC is compr mis d in DMD patients and causes cell membrane instabilit , which start
as soo  as th  fetus can move in ut ro. The DAPC is composed of dystrobrevins, dystro-
glycans, sarco lycans, sarcospan, and syntrophin. Th  most widely used murine model 
for DMD are mdx mice th t arry a onsense mutatio  in xon 23 of the dystrophin gene. 
However, the diseas  phe otype f this murine ode  is milder than the human condi-
tion. While humans display progressive muscle weakness, mice ev lop active muscle 
ti su  degeneratio  and regen ration at a young age, wh ch later on continues at a slower 
pac . The DAPC is aff ct d in DMD and mdx displayi g both common and differential
deficienc e  (Table 1). In mdx mice, α- and β-d s roglyc s are unstable whereas expres-
si  of α-, β-, γ- and δ-sarcoglycans, sarcospan and α1- yntrophin is weak [6–11] nd ex-
p s ion of β1-syntrophi  an  α-dystrobrevin i  absent [12–14]. In DMD patients, the fol-
lowing DAPC protei s re le  exp essed to someti es abse : α- dystroglycan, α-sarco-
glycan, sarc span, α1-syn n, α-dystrobrevin, and neuronal nit ic oxi e synthase 
(nNOS) [10,15–22]. The role f nNOS instability  dx pathology is controversial. Inde d, 
normal nNOS activity reduc d dy trophic s mptoms in one mdx study, wh reas mdx 
mice crossed with NOS-null ice howed no diff renc  i  muscle pathology when com-
pared to mdx mice [23–25]. β- ystr lyca  is still present in DMD skeletal muscle tissue 
[6] an  exp e sio  studies f β1-syntrophin in DMD patie ts a e not yet available. Both
β-dystroglyc n and yntr p in fu c io as signaling proteins. Mo e specifically, β dys-
troglyca  ig als to R s- ela ed C3 b tuli um t x n substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)a e and to mitogen-activated protein kinase (MAPK) through growth factor
r ceptor-bound protein 2 (Grb2). Syntrophin org nizes  signalplex linked to dystrophin
and regulates signaling proteins such as vo tag gated sodium cha nels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Diff rential expr ssion of the main dystrophin-associated protein compl x (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 













α1-syntrophi  weak weak β1-syntrophin absent
α-dystrobre in w ak absent
H mpe ed signal transduc ion d cellular pa hways have b en described in DMD 
with Toll-like receptor/t mor ecrosis f ctor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)-nucle r fa tor kappa-ligh -ch in-enha cer f the activated B cell p thway (NF-Ƙ ), Janus kinas /si nal transducer and activator of tra scription pro ins, and the 
trans-fo ming g wth factor-β (TGF-β) pathways having been extens vely studied and 
cons d-ered f r therapeutic targeting [28,29]. Due to the imp rtant nflammatory aspect 
of the diseas , glu ocorticoids (GC ) are the drugs of choice in DMD with their major 
mode of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear f ctor of activ ted T-c lls (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging o the l rger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B activi y
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in, respectively, a protein kinase C (PKC)-dependent and PKC-independent manner. This
difference in regulation might explain why aldose reductase inhibitors are able to inhibit
high glucose-induced NF-
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and absorb shocks during muscle contraction [4,5]. This shock-absorbing effect of the 
DAPC is compromised in DMD patients and causes cell membrane instability, which start 
as soon as the fetus can move in utero. The DAPC is composed of dystrobrevins, dystro-
glycans, sarcoglycans, sarcospan, and syntrophin. The most widely used murine model 
for DMD are mdx mice that carry a nonsense mutation in exon 23 of the dystrophin gene. 
However, the disease phenotype of this murine model is milder than the human condi-
tion. While humans display progressive muscle weakness, mice develop active muscle 
tissue degeneration and regeneration at a young age, which later on continues at a slower 
pace. The DAPC is affected in DMD and mdx displaying both common and differential 
deficiencies (Table 1). In mdx mice, α- and β-dystroglycans are unstable, whereas expres-
sion of α-, β-, γ- and δ-sarcoglycans, sarcospan and α1-syntrophin is weak [6–11] and ex-
pression of β1-syntrophin and α-dystrobrevin is absent [12–14]. In DMD patients, the fol-
lowing DAPC proteins are less expressed to sometimes absent: α- dystroglycan, α-sarco-
glycan, sarcospan, α1-syntrophin, α-dystrobrevin, and neuronal nitric oxide synthase 
(nNOS) [10,15–22]. The role of nNOS instability in mdx pathology is controversial. Indeed, 
normal nNOS activity reduced dystrophic symptoms in one mdx study, whereas mdx 
mice crossed with NOS-null mice showed no difference in muscle pathology when com-
pared to mdx mice [23–25]. β-dystroglycan is still present in DMD skeletal muscle tissue 
[6] and expression studies of β1-syntrophin in DMD patients are not yet available. Both
β-dystroglycan and syntrophin function as signaling proteins. More specifically, β-dys-
troglycan signals to Ras-related C3 botulinum toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such as voltage-gated sodium channels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
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On the other h d, inhibition f aldose redu tase aggrav t s tissue damage in a
in vivo temporal artery s vere c mbined immu odeficiency (SCID) mouse model for
vasculitis. Aldose reductase plays r le in the toxifi ation of 4-hydr xyn nenal (HNE),
a biomarker for lipid per xida . Rittner et al. further inve tigated the relationship
between aldose reductase a d HNE in vasculitis. Sorbinil treatment in a mouse model for
giant cell arteritis induced a twofold and threef ld in rease in, respectively, HNE adducts
and apoptotic cells. Furthermore, stimulation of mononuclear cells with HNE induces the
expression of aldose reductase. The latter might explain why an upregulation of aldose
reductase is observed in T-cells, macrophages and smooth muscular cells surrounding
arteritic lesions together with the presence of HNE in vivo [132]. These observations led
to the hypothesis that aldose reductase interferes with lipid peroxidation and protects the
arterial wall tissue against oxidative damage. Of note, clinical trials have been conducted
to evaluate the effect of sorbinil for the treatment of diabetic retinopathy.
3. Discussion
GCs remain the mainstay of treatment today yet induce burdensome secondary effects
in DMD patients [28]. The need persists for novel therapeutic avenues. Many researchers
are focusing on gene therapy in order to restore functional dystrophin protein. Ataluren
was the first drug approved by the FDA that addresses the underlying cause of DMD,
namely the lack of functional dystrophin protein. Presumably, ataluren acts by stimulating
the implementation of near-cognate tRNA’s selectively at the nonsense codon site, with
the production of functional dystrophin protein as a result [142–144]. Eteplirsen has
also received FDA approval for the treatment of DMD. Eteplirsen is a form of antisense
oligonucleotide treatment that uses exon skipping in order to restore the reading frame
and gives rise to an altered yet functional form of the dystrophin protein. Gene therapy is
promising; however, there are some concerns regarding safety, efficacy, etc.
In this review, therapeutic molecules associated with the PKA-p38MAPK-NFAT5-
organic osmolytes pathway are discussed in view of a supportive treatment for DMD. Ucns
can upregulate PKA and may be worth considering in DMD clinical trials in conjunction
with IL-6. Ucns belong to the corticotropin-releasing factor (CRF) and show both central
and peripheral actions. In animals, it suppresses appetite, enhances locomotor activity,
and has an anxiogenic effect along with a pro-inflammatory-inducing effect in the skin. In
humans, Ucns lower the blood pressure [145,146]. More physiological studies in humans
are needed before usage in DMD clinical studies. As described in a previous review, the p38
MAPK modulator (ALA)/L-car is an uninteresting molecule to consider despite its FDA
approval and promising results in mdx mice. Indeed, it did not show any difference in the
function of extremities in DMD patients [28]. An alternative molecule that alters p38 MAPK
activity is Celecoxib. Celecoxib is used for the treatment of rheumatoid arthritis [147], is
commercially available and may be worth considering in DMD clinical trials. However,
the appearance of gastric ulcers should be kept in mind [147]. The selective inhibitor of
p38 MAPK termed SB203580 and the GSK-3 peptide inhibitor L803-mts could be further
explored in mdx mice.
NFAT5 is located in the cytoplasm of myoblasts, forming aggregates under pro-
inflammatory conditions. Using anti-NFAT5 nanobodies could direct NFAT5 to the nuclei,
which could enhance muscle regeneration. The latter would be achieved by myoblast-
specific anti-NFAT5 nanobodies. In DMD fibroblasts, where NFAT5 is exclusively located
in the nuclei, anti-NFAT5 would take NFAT5 to the cytoplasm, which might reduce fibrosis.
Downstream targets of NFAT5 involved in osmolyte pathways might also be consid-
ered as a supplementary therapeutic option. Aberrant calcium influx and the subsequent
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hyperosmolar environment, induction of organic osmolytes, TNF-α and hsp70 all play
a role in the pathophysiology of DMD [53,148–150]. Besides countering osmotic stress,
organic osmolytes exert a wide variety of effects that could be of importance in the treat-
ment of DMD. The observed body fat-reducing capacities of betaine would be of benefit
to DMD patients for standard GC therapy. In addition, the anti-inflammatory actions of
osmolytes and their additive effects when combined with GCs would need to be elucidated
further. Osmolytes are able to induce a structural conformational change in the AF1/Tau1
domain of the GR, which stimulates the interaction of AF1 with specific binding proteins
such as TATA box binding protein (TBP), CREB binding protein (CBP) and steroid receptor
coactivator-1 (SRC-1) [151,152]. Whether this fully explains a potential additive effect of
osmolytes and GCs remains to be investigated. Of note, the synergistic effect of taurine
and α-methylprednisolone in mdx mice reported by Cozzoli [112] could not be reproduced
in the study of Barker [153]. This discrepancy might be attributed to differences in the
analysis since Cozzoli et al. analysed the increase in muscle strength relative to a previous
recording before treatment started and is thus less affected by individual differences.
Additionally, there are some potential pitfalls for osmolytes as a treatment. As men-
tioned earlier, studies have reported the inability of taurine treatment to increase muscle
taurine levels in mdx mice; however, taurine treatment was able to significantly decrease
inflammation [105,107]. Daily supplementation of taurine (5 g/day) in humans could
not increase the taurine concentration in muscle either, but a potential anti-inflammatory
effect was not investigated [154]. The latter might suggest that taurine levels are strictly
regulated and supposedly, other organic osmolytes such as betaine, MI and sorbitol might
also be subject to compensatory mechanisms of the metabolism. The inability to increase
osmolyte levels upon supplementation might interfere with the long-term therapeutic
effects. Furthermore, Barker et al. reported a negative side effect of high doses of taurine
(16 g/kg/day). High taurine supplementation abrogates liver cysteine dioxygenase and
cysteine sulfinate decarboxylase activity, which results in increased cysteine plasma lev-
els. High levels of cysteine are considered toxic and might be associated with hampered
growth, the latter is observed in taurine-treated mdx mice [105]. The overall effect of
aldose reductase inhibitors in the treatment of dystrophinopathies are difficult to predict.
As previously stated, the inhibition of aldose reductase might exert anti-inflammatory
effects through the modulation of NF-
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troglycan signals to Ras-related C3 botulinum toxin substrate 1 (Rac1) small guanosinetri-
fosfaat (GTP)ase and to mitogen-activated protein kinase (MAPK) through growth factor
receptor-bound protein 2 (Grb2). Syntrophin organizes a signalplex linked to dystrophin
and regulates signaling proteins such as voltage-gated sodium channels along with
plasma membrane calcium pumps and nNOS. DAPC also interacts with calmodulin
which is stimulated by calcium and in turn signals to calcineurin [5,26,27].
Table 1. Differential expression of the main dystrophin-associated protein complex (DAPC) com-
ponents in Duchenne muscular dystrophy (DMD) and in the mdx mouse. 
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Hampered signal transduction and cellular pathways have been described in DMD 
with Toll-like receptor/tumor necrosis factor α (TNF-α)/interleukin 1β (IL-1β)/interleukin 
6 (IL-6)-nuclear factor kappa-light-chain-enhancer of the activated B cell pathway (NF-Ƙ  ), Janus kinase/signal transducer and activator of transcription proteins, and the 
trans-forming growth factor-β (TGF-β) pathways having been extensively studied and 
consid-ered for therapeutic targeting [28,29]. Due to the important inflammatory aspect 
of the disease, glucocorticoids (GCs) are the drugs of choice in DMD with their major 
mode of action residing in the binding to NF-ƘB and MAPKs along with nuclear 
translocation of nuclear factor of activated T-cells (NFAT) [30,31]. The NFAT group 
consists of five tran-scription factors belonging to the larger ReI family which also 
encompasses NF-ƘB. NFATc1-4 are regulated by calcineurin, whereas NFAT5 is a non-
calcineurin mediated 
B activity [139–141]. On the other hand, aldose
reductase inhibitors might abolish its antioxidant actions. This might result in higher
HNE concentrations [132], which is often used as an u come measure for the evaluation
of oxidative stress in mdx mouse. Both posit v and negative con equences of al ose
reductase inhibitors have been reported.
4. Conclusions
Therapeutic targeting of the PKA-p38MAPK-NFAT5-organic osmolyt s p thwa
could be considered as a supportive treatment for DMD in conjunction with genetic
therapy or as putative molecules to be investigated in experimental DMD studies. Surely,
novel therapeutic molecules should be evaluated first in vitro (DMD or mdx myotubes),
subsequently in animal models (mdx mice, golden retriever muscular dystrophy dog)
and may ultimately be tested in DMD/ BMD patients. Nowadays, carrying out clinical
trials is difficult both due to the relative rarity of dystrophinopathies and family expecta-
tions, but are necessary in order to assess the effect of treatment on muscle performance,
cardiomyopathy and osteoporosis in DMD and BMD patients [60].
Several research paths could be further explored such as expression studies of β1-
syntrophin in DMD patients and the effect of celecoxib and the GSK-3 peptide inhibitor
L803-mts. Osmolytes also make interesting compounds for the treatment of DMD due
to their compatibility with GCs, anti-inflammatory and antioxidant actions. However,
further investigation will be needed to find the optimal effective dose/treatment scheme
that results in the highest therapeutic profit.
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Abbreviation Meaning
AKAP A-kinase anchor protein
AKAP13 A-kinase anchor protein 13
ALA α-lipoic acid
ATP adenosine triphosphate
BGT betaine gamma aminobutyric acid transporter
BMD Becker muscular dystrophy





DAPC dystrophin-associated protein complex
DMD Duchenne muscular dystrophy
FDA Food and Drug Administration
GABA gamma aminobutyric acid
GCs glucocorticoids
GLUT4 glucose transporter type 4
GR glucocorticoid receptor
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GSK-3β glycogen synthase kinase 3 beta
GTP guanosinetrifosfaat
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Hsp70 heat shock protein 70




MAPK mitogen-activated protein kinase
MI myo-inositol
NFAT nuclear factor of activated T- cells
NFAT5 nuclear factor of activated T- cells 5
NFAT5c nuclear factor of activated T- cells c
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Rac 1 Ras-related C3 botulinum toxin substrate
s.c. subcutaneous
SCID severe combined immunodeficiency
SMIT sodium myo-inositol transporter
SRC-1 steroid receptor coactivator 1
TauT Taurine transporter
TBP TATA box binding protein
TGF-β transforming growth factor-β
TNF-α tumor necrosis factor α
TonEBP Tonicity-responsive enhancer binding protein
Ucns urocortins
VCAM-1 vascular cell adhesion molecule 1
VSMC vascular smooth muscle cells
xIL-6R anti-interleukin-6 receptor antibody
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